Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with current survival rates exceeding 90%. As cure rates improve, increasing attention is focused on survivor quality of life, including fertility. It is generally accepted that cancer treatments in childhood may interfere with gonadal function, reducing the pool of primordial follicles and consequently causing premature menopause in women. Anti-Mullerian hormone (AMH) levels is a valuable quantitative indicator of ovarian reserve, being directly related to the number of antral follicles. The evaluation of this hormone makes it possible to identify women at risk of early menopause and to propose them interventions for monitoring and preservation of oocytes, allowing girls to be able to have children once they reach adulthood. The objective of this study is to determine ovarian reserve in girls with ALL before and after treatment by means of the evaluation of the AMH assay.
Study Type
OBSERVATIONAL
Enrollment
10
IRCCS Burlo Garofolo
Trieste, Italy
RECRUITINGEvaluation of blood AMH levels before ALL treatment
AMH levels will be evaluated in peripheral blood
Time frame: Within one months from ALL diagnosis
Evaluation of blood AMH levels after ALL treatment
AMH levels will be evaluated in peripheral blood
Time frame: 24 months after ALL diagnosis
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.